CA - Numinus launches psychedelic-assisted therapy program for chronic/serious illness

• Numinus Wellness ( OTCQX:NUMIF ) on Friday said it launched its Ketamine for Chronic and Serious Medical Illness Program to provide the psychedelic therapy.
• The program will be introduced first in Numinus' clinics in Utah, British Columbia and Quebec and the company plans to expand to other clinics in later months.
• The program will offer ketamine-assisted therapy and care will be provided by professionals who are trained in chronic and serious medical illness.
• "Numinus' program addresses this gap by providing safe, evidence-based ketamine-assisted therapy that is specifically designed for this patient population and serves as an adjunct to patients' existing treatment," said Neil Barclay, VP, Product and Protocol Development, Numinus.

For further details see: